Finerenone

Nonsteroidal Mineralocorticoid-Receptor Antagonist — CARDIOVASCULAR SYSTEM

Key facts

Finerenone is an onp drug in the Nonsteroidal Mineralocorticoid-Receptor Antagonist class catalogued in DrugCentral. It was first approved by the FDA in 2021. Its mechanism of action is classified as Mineralocorticoid Receptor Antagonists. DrugCentral lists 1 molecular target, including NR3C2. Recorded indications include Chronic kidney disease (CKD) associated with type 2 diabetes (T2D).

• Approval status: onp (first approved 2021 by the FDA).
• Drug class: Nonsteroidal Mineralocorticoid-Receptor Antagonist.
• Mechanism of action: Mineralocorticoid Receptor Antagonists.
• Molecular targets: NR3C2 (1 listed in DrugCentral).
• Indications: Chronic kidney disease (CKD) associated with type 2 diabetes (T2D).
• ATC code: C03DA05 (Aldosterone antagonists).
• Molecular formula: C21H22N4O3; molecular weight 378.43 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (1)

• Chronic kidney disease (CKD) associated with type 2 diabetes (T2D)

Contraindications (2)

• Addison's disease
• Adrenal insufficiency

Mechanism & targets

• Mechanism of action (MoA): Mineralocorticoid Receptor Antagonists
• Established pharmacologic class: Nonsteroidal Mineralocorticoid-Receptor Antagonist

Molecular targets (1)

Target	Gene	Action	Activity
Mineralocorticoid receptor	NR3C2	antagonist	IC50 7.77

Regulatory approvals (3)

Date	Agency	Marketed as	Applicant	Orphan
2022-03-28	PMDA	—	Bayer Yakuhin, Ltd.
2022-02-16	EMA	—	BAYER AG
2021-07-09	FDA	—	BAYER HLTHCARE

ATC classification

ATC code	Therapeutic hierarchy
C03DA05	CARDIOVASCULAR SYSTEM › DIURETICS › ALDOSTERONE ANTAGONISTS AND OTHER POTASSIUM-SPARING AGENTS › Aldosterone antagonists

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Glomerular filtration rate decreased	1217.3
Hyperkalaemia	726.6
Blood potassium increased	535.1
Blood creatinine increased	528.0
Urine albumin/creatinine ratio increased	485.7
Renal impairment	216.4
Urine albumin/creatinine ratio decreased	86.7
Product prescribing issue	75.5
Acute kidney injury	73.2
Albuminuria	62.8
Albumin urine present	60.6
Hyponatraemia	49.7

Chemical structure

• Molecular formula: C₂₁H₂₂N₄O₃
• Molecular weight: 378.43 g/mol
• CAS number: —
• InChIKey: BTBHLEZXCOBLCY-QGZVFWFLSA-N
• PubChem CID: 60150535

CCOC1=NC=C(C2=C1[C@@H](C(=C(N2)C)C(=O)N)C3=C(C=C(C=C3)C#N)OC)C

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Finerenone used for?

DrugCentral lists the following indications for Finerenone: Chronic kidney disease (CKD) associated with type 2 diabetes (T2D).

How does Finerenone work?

Finerenone is classified as Mineralocorticoid Receptor Antagonists; its molecular targets in DrugCentral include NR3C2 (antagonist).

When was Finerenone first approved?

Finerenone was first approved by the FDA in 2021.

What drug class does Finerenone belong to?

Finerenone is in the Nonsteroidal Mineralocorticoid-Receptor Antagonist class.

What is the chemical formula of Finerenone?

Finerenone has the molecular formula C21H22N4O3 and a molecular weight of 378.43 g/mol.

Sources

• DrugCentral drug card 5465 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL2181927 — compound record and bioactivity
• PubChem CID 60150535 — chemical identifiers
• DrugBank DB16165 — drug record
• FDA UNII DE2O63YV8R — substance identity
• DailyMed: FDA labels for Finerenone — current prescribing information (label search)
• UniProt P08235 (NR3C2) — target protein
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral

How this page is built: methodology · editorial policy & corrections.